Emergent BioSolutions announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), described as a third generation vaccine being developed as part of Emergent’s anthrax franchise consisting of BioThrax (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909. Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions, commented, “We believe this third generation anthrax vaccine has the potential to exhibit advanced characteristics such as requiring fewer doses, generating an enhanced immune response, and having a favorable shelf life. If successful, this could be an attractive candidate for the government’s growing arsenal of medical countermeasures.”

http://www.businesswire.com/news/home/20101227005257/en/Emergent-BioSolutions-Starts-Phase-Clinical-Trial-Generation